仁度生物(688193) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥40,684,805.73, a decrease of 9.22% compared to ¥44,815,148.38 in the same period last year[4] - Net profit attributable to shareholders decreased by 67.04% to ¥1,220,931.14 from ¥3,703,907.82 year-on-year[4] - Basic and diluted earnings per share decreased by 66.67% to ¥0.03 from ¥0.09 year-on-year[4] - The company reported a total comprehensive income of CNY 1,166,514.79 for Q1 2025, compared to CNY 3,772,583.60 in Q1 2024, a decline of 69.0%[20] Cash Flow - The net cash flow from operating activities fell by 134.97%, resulting in a negative cash flow of ¥2,844,554.71 compared to a positive cash flow of ¥8,135,229.74 in the previous year[4][8] - The company reported a net cash flow from financing activities of -703,907.44, resulting in a total outflow of 12,233,123.04[24] - Cash inflow from investment activities was CNY 476,509,753.77 in Q1 2025, significantly higher than CNY 50,736,511.42 in Q1 2024[22] - Cash and cash equivalents increased to RMB 328,927,414.04 from RMB 261,582,058.68, representing a growth of about 25.7%[13] Expenses and Costs - Total operating costs increased to CNY 44,161,459.69 in Q1 2025, up from CNY 43,739,944.96 in Q1 2024, representing a rise of 1.0%[18] - The company incurred a total operating expense of CNY 44,979,046.54 in Q1 2025, compared to CNY 47,559,475.95 in Q1 2024, indicating a decrease of 5.3%[22] - Research and development expenses totaled ¥8,247,774.22, representing 20.27% of operating revenue, down from 22.71% in the previous year[5] - Research and development expenses were CNY 8,247,774.22 in Q1 2025, down from CNY 10,176,017.01 in Q1 2024, a reduction of 19.0%[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥986,629,392.53, a decrease of 0.78% from ¥994,358,320.65 at the end of the previous year[5] - The total liabilities amounted to CNY 73,204,918.58, a decrease from CNY 82,478,947.62 in the previous period[16] - The total current liabilities decreased to RMB 65,294,940.62 from RMB 74,415,169.08, indicating a reduction of approximately 12.3%[15] - The company held trading financial assets of RMB 442,709,777.78, down from RMB 510,959,655.56, a decrease of approximately 13.3%[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 3,250[10] - The largest shareholder, Ji Jinliang, holds 7,858,357 shares, representing 19.65% of the total shares[10] - The company repurchased 1,291,428 shares, representing 3.23% of the total share capital[12] Strategic Changes - The company attributed the decline in revenue and profit primarily to a change in the VAT calculation method for in vitro diagnostic reagent products, effective January 1, 2025[7] - The company has not disclosed any significant new strategies or product developments during the reporting period[12] - The company will first implement new accounting standards starting from 2025[24]